Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
ALXN [NASD]
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E93.43 EPS (ttm)1.99 Insider Own0.70% Shs Outstand197.81M Perf Week13.89%
Market Cap36.78B Forward P/E32.34 EPS next Y5.75 Insider Trans-5.91% Shs Float196.46M Perf Month10.21%
Income400.60M PEG3.05 EPS next Q1.16 Inst Own97.30% Short Float1.69% Perf Quarter11.30%
Sales1.92B P/S19.14 EPS this Y-0.80% Inst Trans-0.20% Short Ratio2.79 Perf Half Y21.37%
Book/sh14.56 P/B12.77 EPS next Y14.75% ROA12.10% Target Price198.57 Perf Year69.54%
Cash/sh8.06 P/C23.07 EPS next 5Y30.67% ROE15.50% 52W Range110.67 - 186.47 Perf YTD39.92%
Dividend- P/FCF104.54 EPS past 5Y44.70% ROI10.20% 52W High2.05% Beta0.68
Dividend %- Quick Ratio5.30 Sales past 5Y43.00% Gross Margin91.30% 52W Low71.94% ATR6.58
Employees1774 Current Ratio5.60 Sales Q/Q38.50% Oper. Margin39.10% RSI (14)69.10 Volatility3.58% 3.76%
OptionableYes Debt/Eq0.03 EPS Q/Q72.90% Profit Margin20.90% Rel Volume1.52 Prev Close185.92
ShortableYes LT Debt/Eq0.01 EarningsOct 23 BMO Payout0.00% Avg Volume1.19M Price190.29
Recom1.90 SMA2012.48% SMA5013.69% SMA20017.55% Volume1,803,899 Change2.35%
25-Apr-14Reiterated Stifel Buy $219 → $220
11-Mar-14Reiterated UBS Buy $185 → $202
11-Mar-14Reiterated Stifel Buy $207 → $219
06-Mar-14Reiterated Barclays Overweight $181 → $193
10-Feb-14Reiterated Deutsche Bank Buy $125 → $205
31-Jan-14Reiterated Stifel Buy $138 → $207
31-Jan-14Reiterated Canaccord Genuity Buy $161 → $200
31-Jan-14Reiterated Barclays Overweight $141 → $181
30-Jan-14Reiterated Brean Capital Buy $142 → $200
10-Jan-14Reiterated Barclays Overweight $127 → $141
06-Jan-14Reiterated UBS Buy $130 → $150
06-Jan-14Reiterated Canaccord Genuity Buy $138 → $161
25-Oct-13Reiterated Stifel Buy $131 → $138
25-Oct-13Reiterated Barclays Overweight $121 → $127
26-Jul-13Reiterated Barclays Overweight $118 → $121
26-Apr-13Reiterated UBS Buy $120 → $123
24-Sep-12Reiterated Canaccord Genuity Buy $115 → $132
25-Apr-12Reiterated Canaccord Genuity Buy $95 → $100
25-Apr-12Reiterated Barclays Overweight $84 → $104
26-Mar-12Initiated Canaccord Genuity Buy $95
24-Oct-14 12:06PM  Alexion Pharmaceuticals (ALXN) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
09:20AM  Company News for October 24, 2014 Zacks
23-Oct-14 06:10PM  Celgene, Alexion Earnings Top Views, Send Stocks Flying Investor's Business Daily +7.30%
05:12PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:16PM  Major Indexes Close Higher; Lannett Breaks Out at Investor's Business Daily
04:15PM  Researchers to Present Data on SolirisĀ® (eculizumab) as a Treatment for Patients with aHUS at ASN 2014 Annual Meeting Business Wire
03:08PM  Alexion Pharmaceuticals: Nice Earnings, Too Expensive? at Barrons.com
01:15PM  Alexion Beats on Earnings & Revenues in Q3, Guides Up Zacks
12:14PM  Celgene, Alexion Both Beat And Raise, Stocks Rise at Investor's Business Daily
10:28AM  Stocks Jump To Early Gains; Lannett, Alexion Break Out at Investor's Business Daily
10:00AM  Alexion Pharmaceuticals Inc Earnings Call scheduled for 10:00 am ET today CCBN
07:18AM  Alexion Pharma quarterly adj profit beats, raises forecast again Reuters
07:07AM  Q3 2014 Alexion Pharmaceuticals Inc Earnings Release - Before Market Open CCBN
06:40AM  Alexion tops Street 3Q forecasts AP
06:30AM  Alexion Reports Third Quarter 2014 Results Business Wire
22-Oct-14 05:01PM  Fortinet Gains After Hours, But Yelp Dives at Investor's Business Daily
03:25PM  Video: Top 4 Earnings Reports To Watch Thursday at Investor's Business Daily
21-Oct-14 07:56PM  Biogen Leads 5 Top Biotech Stocks As Earnings Loom at Investor's Business Daily
04:05PM  Will Alexion (ALXN) Earnings Suffer Due to Higher Costs? Zacks
20-Oct-14 06:01PM  Alexion: Keeping Up The Suspense Ahead Of Q3 Earnings at Investor's Business Daily
18-Oct-14 08:02AM  Celgene, Alexion Among 4 IBD 50 Medicals To Report at Investor's Business Daily
16-Oct-14 03:30PM  Alexion (ALXN) Seeks Japanese Approval for Asfotase Alfa Zacks
08:35AM  Analyst Top Biotech Stocks Could Explode After Huge Sell-Off at 24/7 Wall St.
15-Oct-14 04:57PM  Markets Rebound After Getting Crushed Intraday, Still Close Lower Benzinga
08:03AM  Alexion Eyes European Headquarters in Zurich on Expansion Push at Bloomberg
06:30AM  Alexion Submits NDA in Japan for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia Business Wire
14-Oct-14 04:23PM  Stocks Close Mixed, Surrendering Some Early Gains at Investor's Business Daily
11:22AM  A Drug Regrew A Little Girl's Missing Bones. How Much Should That Cost? at Forbes
13-Oct-14 08:40AM  UBS Very Positive on Top Biotech Stocks Ahead of Earnings at 24/7 Wall St.
09-Oct-14 10:00AM  Alexion Pharmaceuticals to Report Third Quarter 2014 Results on Thursday, October 23, 2014 Business Wire
07:03AM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online
06:30AM  Alexion Board of Directors Appoints New Chairman and Creates the New Position of Lead Independent Director Business Wire
08-Oct-14 06:19PM  Three Leading Medicals Staying Healthy In Correction at Investor's Business Daily +5.04%
05:49PM  Video: 3 Big Cap Biotechs Bucking Market Correction at Investor's Business Daily
05:07PM  Stocks Soar After Fed Minutes; Leaders Reverse Higher at Investor's Business Daily
07:14AM  Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update Zacks
07-Oct-14 05:17PM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online
04:00PM  Alexion Announces the Passing of Max Link, Ph.D., Chairman of the Companys Board of Directors Business Wire
06-Oct-14 09:47AM  Better-than-expected jobs data helped benchmarks end in the green on Friday Zacks
06:43AM  Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.0% Zacks
04-Oct-14 08:02AM  Medical Stocks End Week On High Note, Biotechs Lead at Investor's Business Daily
03-Oct-14 06:47PM  Medical Stocks Hang Tough As Market Falls at Investor's Business Daily +6.03%
06:22PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
01:32PM  Nasdaq, S&P 500 Aim For 50-Day Lines; Alexion Breaks Out at Investor's Business Daily
01-Oct-14 02:41PM  Russell 2000 officially in correction CNBC
30-Sep-14 06:24PM  Growth Prospects Still Solid At Alexion Pharmaceuticals at Investor's Business Daily
29-Sep-14 06:32PM  Biotech Stocks Rebound On Strong Earnings, New Drugs at Investor's Business Daily
05:34PM  Sometimes Losses Should Be Cut Before They Get To 7% Or 8% Investor's Business Daily
10:15AM  Insider Trading Alert - MWV, RSG And ALXN Traded By Insiders at TheStreet
25-Sep-14 10:50AM  Short Sellers Make Moves in Key Biotech Stocks at 24/7 Wall St.
08:35AM  5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential at 24/7 Wall St.
24-Sep-14 04:20PM  US STOCKS-Wall St rallies, S&P back above 14-day moving average Reuters +6.32%
04:16PM  Stocks End Skid; Vertex, Alexion Lead Biotech Rebound at Investor's Business Daily
03:05PM  Stocks Up In Afternoon; Hasbro Jumps On Disney Deal at Investor's Business Daily
01:20PM  Stocks Hold Solid Gains; CyberArk Soars In Debut at Investor's Business Daily
10:06AM  Biotech Stock Roundup: Auxilium an Acquisition Target, Amgen Submits another BLA Zacks
22-Sep-14 02:20PM  Is Illumina (ILMN) Worth Adding to Your Portfolio? Zacks
19-Sep-14 07:36PM  IBD 50 Stocks Setting Up, Including These 5 Medicals at Investor's Business Daily
17-Sep-14 01:04PM  SNN, ALXN And ACT, 3 Health Care Stocks Pushing The Sector Lower at TheStreet
09:37AM  Stock Market News for September 17, 2014 Zacks
07:49AM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online
07:30AM  Alexion Strengthens and Broadens Its Executive Leadership Team Business Wire
15-Sep-14 02:55PM  Nasdaq Falls Hard, But Apple Resilient On iPhone Orders at Investor's Business Daily
14-Sep-14 05:30PM  Improved Survival Observed in Pediatric Patients with Severe Hypophosphatasia (HPP) Who Were Treated with Investigational Asfotase Alfa for Up to Five Years Business Wire
13-Sep-14 08:02AM  Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers at Investor's Business Daily
11-Sep-14 09:20AM  Short Sellers Remain Vigilant Against Biotechs at 24/7 Wall St.
10-Sep-14 01:25PM  Stocks Turn Higher After Soft Start; U.S. Silica Jumps at Investor's Business Daily
09-Sep-14 04:30PM  Alexion's Asfotase Alfa Gets Japanese Orphan Drug Status Zacks
08-Sep-14 09:10AM  SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks at 24/7 Wall St.
06:30AM  Asfotase Alfa Granted Orphan Drug Designation in Japan Business Wire
05-Sep-14 06:45PM  Alexion Pharmaceuticals: FDA Findings An Easy Fix at Investor's Business Daily
12:03PM  Insider Trading Alert - BRCM, ALXN And JLL Traded By Insiders at TheStreet
04-Sep-14 04:00PM  Alexion Pharmaceuticals' Soliris Wins NICE Backing for aHUS Zacks
03-Sep-14 07:01PM  NICE Recommends Commissioning of Eculizumab (SolirisĀ®) for All Patients with aHUS in England Business Wire
11:50AM  Credit Suisse Positive on Some Biotechs, Very Cautious on Others at 24/7 Wall St.
02-Sep-14 10:45AM  Insider Trading Alert - TKR, MTOR And ALXN Traded By Insiders at TheStreet
28-Aug-14 03:30PM  Repros Reports Encouraging Late-Stage Data on Androxal Zacks
10:00AM  Alexion to Present at Investor Conferences Business Wire
27-Aug-14 04:13PM  Alexion's Soliris Manufacturing Facility Fails to Please FDA Zacks
01:03PM  3 Drugs Stocks Dragging The Industry Down at TheStreet
10:25AM  Rising Short Interest in Biotech Stocks 24/7 Wall St.
09:32AM  Biotech Stock Roundup: Biotechs Surge on InterMune Acquisition Deal, Focus on More M&As Zacks
26-Aug-14 02:24PM  Alexion is Tagged by the FDA for Production Problems -- Again at The Wall Street Journal
25-Aug-14 07:02AM  ALEXION PHARMACEUTICALS INC Files SEC form 8-K, Other Events EDGAR Online
06:30AM  Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation Business Wire
20-Aug-14 10:08AM  Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus Zacks
19-Aug-14 04:25PM  Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 Zacks
18-Aug-14 01:46PM  Jazz, Celgene Lead Top 4 Drugmaker Profit Margins at Investor's Business Daily
14-Aug-14 04:02PM  Alexion CEO Receives Nearly $17 Million for Sale of Company Stock Gurufocus
03:10PM  [video] Red hot biotech stocks at CNBC
13-Aug-14 04:57PM  Researchers to Present New Data on Asfotase Alfa in Pediatric Patients with Hypophosphatasia at the American Society for Bone and Mineral Research 2014 Annual Meeting Business Wire
08-Aug-14 04:45PM  GW Pharma, Insys Face Off In Cannabis Drug Space at Investor's Business Daily
01:03PM  Today's Stocks Driving Success For The Health Care Sector at TheStreet
10:28AM  Wall Street Transcript Interview with Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics Corporation (SPNC) Wall Street Transcript
10:00AM  VIVUS Reports Narrower-than-Expected Loss on Qsymia Sales Zacks
07-Aug-14 06:02PM  Double-Bottom Bases Demand A Tenacious Attention Span Investor's Business Daily
11:40AM  NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales Zacks
05-Aug-14 01:00PM  Actavis Beats on Q2 Earnings & Revs, Provides 2015 Outlook Zacks
04-Aug-14 10:10AM  Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss Zacks
08:37AM  Politicians Shouldn't Question Drug Costs But Rather Their Value. Lessons From Soliris And Sovaldi. at Forbes
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moriarty John BSVP & General CounselOct 06Option Exercise95.6510,000956,50034,532Oct 08 04:55 PM
Moriarty John BSVP & General CounselOct 06Sale179.0010,0001,790,00024,532Oct 08 04:55 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 03Option Exercise42.6610,025427,667116,893Oct 07 08:13 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerOct 03Sale172.4110,0251,728,374106,868Oct 07 08:13 PM
BELL LEONARDCEOSep 26Sale165.1260,0009,906,901948,886Sep 26 05:52 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerSep 24Sale159.507612,122106,868Sep 26 05:53 PM
BELL LEONARDCEOSep 18Sale161.4512,3882,000,0431,008,886Sep 18 05:33 PM
BELL LEONARDCEOSep 16Option Exercise17.6532,047565,6301,053,321Sep 18 05:33 PM
BELL LEONARDCEOSep 16Sale160.2632,0475,136,0051,021,274Sep 18 05:33 PM
BELL LEONARDCEOSep 10Sale165.3812,1992,017,4711,021,274Sep 12 08:59 PM
Carmichael ClareSVP, Chief HR OfficerSep 02Sale169.4630451,51616,272Sep 04 04:34 PM
BELL LEONARDCEOAug 15Option Exercise17.6535,000617,7501,062,186Aug 18 05:46 PM
BELL LEONARDCEOAug 15Sale170.0635,0005,952,1001,027,186Aug 18 05:46 PM
BELL LEONARDCEOAug 14Option Exercise17.6535,000617,7501,062,186Aug 18 05:46 PM
BELL LEONARDCEOAug 14Sale165.9235,0005,807,3661,027,186Aug 18 05:46 PM
BELL LEONARDCEOAug 13Option Exercise17.6524,542433,1661,051,728Aug 13 07:10 PM
BELL LEONARDCEOAug 13Sale162.5224,5423,988,5941,027,186Aug 13 07:10 PM
BELL LEONARDCEOAug 12Option Exercise17.6580,4581,420,0841,107,644Aug 13 07:10 PM
BELL LEONARDCEOAug 12Sale160.1680,45812,885,9101,027,186Aug 13 07:10 PM
BELL LEONARDCEOAug 04Sale157.885,145812,2931,027,186Aug 05 04:55 PM
Hallal DavidEVP, Chief Commercial OfficerAug 04Sale158.001,349213,142118,616Aug 05 04:55 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerAug 04Sale157.421,662261,632106,944Aug 05 04:55 PM
Carmichael ClareSVP, Chief HR OfficerAug 04Sale158.2318429,11416,576Aug 05 04:54 PM
Sinha VikasEVP & CFOAug 04Sale157.821,525240,676162,770Aug 05 04:54 PM
BELL LEONARDCEOJul 30Option Exercise17.6520,489361,6311,052,820Jul 30 05:08 PM
BELL LEONARDCEOJul 30Sale165.6920,4893,394,8331,032,331Jul 30 05:08 PM
BELL LEONARDCEOJul 29Option Exercise17.651,20021,1801,033,531Jul 30 05:08 PM
BELL LEONARDCEOJul 29Sale164.931,200197,9161,032,331Jul 30 05:08 PM
BELL LEONARDCEOJul 28Option Exercise17.65105,6001,863,8401,137,931Jul 30 05:08 PM
BELL LEONARDCEOJul 28Sale162.38105,60017,146,8011,032,331Jul 30 05:08 PM
BELL LEONARDCEOJun 20Option Exercise11.9290,2801,076,1381,122,611Jun 23 06:26 PM
BELL LEONARDCEOJun 20Sale163.6090,28014,770,1871,032,331Jun 23 06:26 PM
MACKAY MARTINEVP & Global Head of R&DJun 12Option Exercise104.8625,0002,621,50049,426Jun 13 05:31 PM
MACKAY MARTINEVP & Global Head of R&DJun 12Sale166.4225,0004,160,56524,426Jun 13 05:31 PM
KELLER WILLIAM RDirectorJun 05Option Exercise96.353,425329,99915,701Jun 06 04:14 PM
KELLER WILLIAM RDirectorJun 05Sale170.003,425582,25012,276Jun 06 04:14 PM
Veneman Ann MDirectorJun 04Sale170.011,236210,1324,682Jun 06 04:14 PM
BELL LEONARDCEOMay 27Option Exercise11.9270,000834,4001,102,331May 29 05:10 PM
BELL LEONARDCEOMay 27Sale166.1670,00011,631,3491,032,331May 29 05:10 PM
BELL LEONARDCEOMay 20Option Exercise10.5270,000736,1441,102,331May 22 04:49 PM
BELL LEONARDCEOMay 20Sale155.9670,00010,917,5281,032,331May 22 04:49 PM
MACKAY MARTINEVP & Global Head of R&DMay 14Sale160.853,574574,87824,426May 15 05:11 PM
PARVEN ALVIN SDirectorMay 13Option Exercise16.8312,276206,60517,116May 15 05:11 PM
PARVEN ALVIN SDirectorMay 13Sale160.7812,2761,973,7354,840May 15 05:11 PM
BELL LEONARDCEOApr 29Option Exercise10.2966,210681,3011,098,541Apr 30 05:03 PM
BELL LEONARDCEOApr 29Sale156.2666,21010,346,2561,032,331Apr 30 05:03 PM
BELL LEONARDCEOApr 28Option Exercise10.293,79038,9991,036,121Apr 30 05:03 PM
BELL LEONARDCEOApr 28Sale155.123,790587,9051,032,331Apr 30 05:03 PM
MADRI JOSEPH ADirectorMar 11Option Exercise9.5160,000570,600239,217Mar 13 05:03 PM
MADRI JOSEPH ADirectorMar 11Sale178.6160,00010,716,300179,217Mar 13 05:03 PM
Carmichael ClareSVP, Chief HR OfficerMar 03Sale174.7730553,30516,760Mar 04 05:35 PM
PARVEN ALVIN SDirectorFeb 11Sale174.062,471430,1024,840Feb 13 05:00 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 10Sale167.311,635273,552101,308Feb 10 06:47 PM
MADRI JOSEPH ADirectorFeb 07Option Exercise4.9330,000147,900209,217Feb 10 06:46 PM
MADRI JOSEPH ADirectorFeb 07Sale159.0030,0004,770,000179,217Feb 10 06:46 PM
Sinha VikasEVP & CFOFeb 07Sale155.571,620252,029137,900Feb 10 06:46 PM
Moriarty John BSVP & General CounselFeb 07Sale155.601,036161,19822,232Feb 10 06:46 PM
Wright Frank JSVP, President Alxn Pharm IntlFeb 07Sale155.571,098170,81919,670Feb 10 06:48 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 07Sale155.571,620252,030102,943Feb 10 06:47 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 07Sale155.571,610250,461113,965Feb 10 06:47 PM
BELL LEONARDCEOFeb 07Sale155.564,620718,672986,696Feb 10 06:48 PM
Carmichael ClareSVP, Chief HR OfficerFeb 07Sale155.561,006156,49613,765Feb 10 06:48 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 06Option Exercise93.833,800356,55498,618Feb 10 06:47 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerFeb 06Sale155.113,800589,41894,818Feb 10 06:47 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 06Sale156.95101,570113,965Feb 10 06:47 PM
Carmichael ClareSVP, Chief HR OfficerFeb 04Sale153.63760116,7598,703Feb 05 07:56 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 04Sale153.632,390367,176105,830Feb 05 07:56 PM
BELL LEONARDCEOFeb 04Sale153.638,8701,362,698963,276Feb 05 07:56 PM
Sinha VikasEVP & CFOFeb 04Sale153.632,700414,801129,775Feb 05 07:57 PM
MATHIS LARRYDirectorFeb 03Option Exercise23.5580,7291,901,540110,185Feb 05 07:57 PM
LINK MAXDirectorFeb 03Sale155.1640,0006,206,21958,574Feb 05 07:57 PM
Sinha VikasEVP & CFOFeb 03Sale157.14852133,883132,475Feb 05 07:57 PM
MATHIS LARRYDirectorFeb 03Sale157.5080,72912,714,58629,456Feb 05 07:57 PM
BELL LEONARDCEOFeb 03Sale157.142,920458,849972,146Feb 05 07:56 PM
Hallal DavidEVP, Chief Commercial OfficerFeb 03Sale157.14729114,555108,220Feb 05 07:56 PM
BELL LEONARDCEOJan 29Sale133.812,660355,929975,066Jan 31 05:29 PM
Sinha VikasEVP & CFOJan 29Sale133.43994132,633133,327Jan 31 05:29 PM
Hallal DavidEVP, Chief Commercial OfficerJan 29Sale133.4572997,283108,949Jan 31 05:29 PM
SQUINTO STEPHEN PEVP, Chief Global Ops. OfficerJan 29Sale133.311,118149,039103,068Jan 31 05:30 PM
BELL LEONARDCEOJan 22Option Exercise10.2912,817131,887990,543Jan 22 05:52 PM
BELL LEONARDCEOJan 22Sale141.4112,8171,812,397977,726Jan 22 05:52 PM
BELL LEONARDCEOJan 21Option Exercise8.19110,930908,0651,137,409Jan 22 05:52 PM
BELL LEONARDCEOJan 21Sale140.91110,93015,631,693977,726Jan 22 05:52 PM
BELL LEONARDCEOJan 17Option Exercise6.9032,689225,5541,076,351Jan 22 05:52 PM
BELL LEONARDCEOJan 17Sale140.2032,6894,582,8661,043,662Jan 22 05:52 PM
BELL LEONARDCEOJan 13Option Exercise6.9015,845109,3311,059,507Jan 15 06:19 PM
BELL LEONARDCEOJan 13Sale135.2515,8452,143,0361,043,662Jan 15 06:19 PM
BELL LEONARDCEOJan 10Option Exercise6.9011,70580,7651,043,662Jan 10 05:26 PM
BELL LEONARDCEOJan 10Sale135.0011,7051,580,1751,031,957Jan 10 05:26 PM
BELL LEONARDCEOJan 09Option Exercise6.901,0397,1691,032,996Jan 10 05:26 PM
BELL LEONARDCEOJan 09Sale135.051,039140,3171,031,957Jan 10 05:26 PM
BELL LEONARDCEOJan 08Option Exercise5.426,41134,7761,038,368Jan 10 05:26 PM
BELL LEONARDCEOJan 08Sale134.936,411865,0361,031,957Jan 10 05:26 PM
BELL LEONARDCEODec 19Option Exercise5.1835,000181,3001,066,957Dec 20 04:24 PM
BELL LEONARDCEODec 19Sale129.9035,0004,546,5001,031,957Dec 20 04:24 PM
Hallal DavidEVP, Chief Commercial OfficerDec 18Option Exercise17.987,295131,164116,973Dec 20 04:25 PM
Sinha VikasEVP & CFODec 18Option Exercise17.6532,026565,259166,347Dec 20 04:24 PM
BELL LEONARDCEODec 18Option Exercise5.62145,664818,5701,171,957Dec 20 04:24 PM
BELL LEONARDCEODec 18Sale125.49140,00017,569,1491,031,957Dec 20 04:24 PM
Sinha VikasEVP & CFODec 18Sale127.8132,0264,093,243134,321Dec 20 04:24 PM